Enclomiphene and MK-2866 Interaction

Compatible
Researched 90% confidence

Enclomiphene and MK-2866 have a compatible interaction with 90% confidence. Enclomiphene is frequently used as a mini-PCT or on-cycle support with MK-2866 to mitigate testosterone suppression. Enclomiphene stimulates endogenous LH and FSH release, counteracting the mild HPTA suppression caused by MK-2866. This combination can help maintain natural testosterone levels during and after a SARM cycle. Both compounds affect the gonads, so monitoring these systems is recommended.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Half-life: ~10 hours Typical dose: 12.5-25mg oral daily pct, sexual health
estrogen receptorserotonin receptor hepatotoxicpct agentteratogenic
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Enclomiphene, MK-2866). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take Enclomiphene with MK-2866?

Yes, Enclomiphene and MK-2866 can generally be taken together. Enclomiphene is frequently used as a mini-PCT or on-cycle support with MK-2866 to mitigate testosterone suppression. Enclomiphene stimulates endogenous LH and FSH release, counteracting the mild HPTA suppression caused by MK-2866. This combination can help maintain natural testosterone levels during and after a SARM cycle.

Is Enclomiphene and MK-2866 safe together?

Based on documented research, this combination is considered compatible. However, shared safety flags include: hepatotoxic. Monitor accordingly.

What are the interactions between Enclomiphene and MK-2866?

Enclomiphene is frequently used as a mini-PCT or on-cycle support with MK-2866 to mitigate testosterone suppression. Enclomiphene stimulates endogenous LH and FSH release, counteracting the mild HPTA suppression caused by MK-2866. This combination can help maintain natural testosterone levels during and after a SARM cycle. This assessment has 90% confidence and is based on documented research data.

How should I time Enclomiphene and MK-2866?

Enclomiphene has a half-life of ~10 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Enclomiphene vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.